ESMO 2018: TiNivo: Tivozanib Combined With Nivolumab: Safety and Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Tag: Tivozanib
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Authors: Ana M. Molina, Thomas E. Hutson, Dmitry Nosov, Piotr Tomczak, Oleg Lipatov, Cora N. Sternberg, Robert Motzer, Tim Eisen. Click here for link to article.
ASCO GU 2018: Tivozanib Combined With Nivolumab: Phase Ib/II Study in Metastatic Renal Cell Carcinoma
ASCO GU 2018: Tivozanib Combined With Nivolumab: Phase Ib/II Study in Metastatic Renal Cell Carcinoma
KCS 2017: TiNivo, A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma
KCS 2017: TiNivo, A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma
ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
Annual Symposium on Anti-angiogenesis and Immune Therapies for Cancer 2015: Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
Annual Symposium on Anti-angiogenesis and Immune Therapies for Cancer 2015: Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Authors: Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E. Hutson. Click here for link to article.
ASCO 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
ASCO 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib